
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6585120/publications.pdf Version: 2024-02-01



ΔΟΡΙΔΝΟ ΔΝΟΕΙΠΟΟΙ

#	Article	IF	CITATIONS
1	The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma. Biomedicines, 2022, 10, 659.	3.2	6
2	Hypoxia Induces DPSC Differentiation versus a Neurogenic Phenotype by the Paracrine Mechanism. Biomedicines, 2022, 10, 1056.	3.2	17
3	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-1² and IL-6. Pharmaceuticals, 2022, 15, 622.	3.8	7
4	The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy. International Journal of Molecular Sciences, 2021, 22, 3863.	4.1	31
5	Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1957-1971.	2.5	8
6	Targeting DDX3X Helicase Activity with BA103 Shows Promising Therapeutic Effects in Preclinical Glioblastoma Models. Cancers, 2021, 13, 5569.	3.7	6
7	Extracellular Vesicles: New Endogenous Shuttles for miRNAs in Cancer Diagnosis and Therapy?. International Journal of Molecular Sciences, 2020, 21, 6486.	4.1	36
8	Leptin in Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1259, 89-112.	1.6	9
9	Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far. Cancers, 2020, 12, 1448.	3.7	80
10	Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein–Protein Interaction. ACS Chemical Biology, 2020, 15, 1026-1035.	3.4	9
11	AuNP Pyrazolo[3,4- <i>d</i>]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma. ACS Medicinal Chemistry Letters, 2020, 11, 664-670.	2.8	11
12	Crocetin Extracted from Saffron Shows Antitumor Effects in Models of Human Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 423.	4.1	37
13	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1427-1440.	2.5	10
14	Inhibition of autophagy in prostate cancer cells stimulates Tau accumulation and aberrant mitotic spindle. FASEB Journal, 2020, 34, 1-1.	0.5	0
15	Cellular and Molecular Mechanisms Mediated by recPrPC Involved in the Neuronal Differentiation Process of Mesenchymal Stem Cells. International Journal of Molecular Sciences, 2019, 20, 345.	4.1	29
16	Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic. Cancers, 2019, 11, 490.	3.7	7
17	In Vitro Conditioning Determines the Capacity of Dental Pulp Stem Cells to Function as Pericyte-Like Cells. Stem Cells and Development, 2019, 28, 695-706.	2.1	34
18	Chemically stable inhibitors of 14-3-3 protein–protein interactions derived from BV02. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 657-664.	5.2	12

#	Article	IF	CITATIONS
19	Body mass index represents a good predictor of vitamin D status in women independently from age. Clinical Nutrition, 2019, 38, 829-834.	5.0	30
20	Abstract 2201: Preclinical development of novel pyrazolo[3,4-d]pyrimidines structure-based TKIs for the treatment of glioblastoma. , 2019, , .		0
21	KRIT1 loss-of-function induces a chronic Nrf2-mediated adaptive homeostasis that sensitizes cells to oxidative stress: Implication for Cerebral Cavernous Malformation disease. Free Radical Biology and Medicine, 2018, 115, 202-218.	2.9	69
22	Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors. Molecules, 2018, 23, 2369.	3.8	5
23	Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3454-3457.	2.2	20
24	"Vessels in the Stormâ€: Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. International Journal of Molecular Sciences, 2018, 19, 299.	4.1	29
25	Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells. Hormone and Metabolic Research, 2018, 50, 640-647.	1.5	3
26	Plasmin-Binding Tripeptide-Decorated Liposomes Loading Pyrazolo[3,4- <i>d</i>]pyrimidines for Targeting Hepatocellular Carcinoma. ACS Medicinal Chemistry Letters, 2018, 9, 646-651.	2.8	4
27	Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling. Tumor Biology, 2018, 40, 101042831877177.	1.8	7
28	Non-conventional role of haemoglobin beta in breast malignancy. British Journal of Cancer, 2017, 117, 994-1006.	6.4	31
29	Prodrugs of Pyrazolo[3,4- <i>d</i>]pyrimidines: From Library Synthesis to Evaluation as Potential Anticancer Agents in an Orthotopic Glioblastoma Model. Journal of Medicinal Chemistry, 2017, 60, 6305-6320.	6.4	28
30	Leptin contributes to long-term stabilization of HIF-1α in cancer cells subjected to oxygen limiting conditions. Cancer Letters, 2016, 376, 1-9.	7.2	20
31	Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells. Molecular Cancer Therapeutics, 2016, 15, 1535-1544.	4.1	28
32	Clinical correlates of plasma brain-derived neurotrophic factor in post-traumatic stress disorder spectrum after a natural disaster. Psychiatry Research, 2016, 244, 165-170.	3.3	19
33	Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and inÂvitro effects of fenofibrate in GH3 cells. Molecular and Cellular Endocrinology, 2016, 426, 61-72.	3.2	2
34	Serum 25(OH)D seasonality in urologic patients from central Italy. Journal of Photochemistry and Photobiology B: Biology, 2016, 162, 361-366.	3.8	4
35	Adipose-derived stem cells sustain prolonged angiogenesis through leptin secretion. Growth Factors, 2016, 34, 87-96.	1.7	27
36	Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. ChemMedChem, 2015, 10, 2027-2041.	3.2	13

3

#	Article	IF	CITATIONS
37	Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors. Journal of Medicinal Chemistry, 2015, 58, 4590-4609.	6.4	31
38	Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4- <i>d</i>]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma. Journal of Medicinal Chemistry, 2015, 58, 347-361.	6.4	53
39	Abstract 428: Dual E-selectin and CXCR4 inhibition reduces tumor growth and increases the sensitivity to docetaxel in experimental bone metastases of prostate cancer. Cancer Research, 2015, 75, 428-428.	0.9	3
40	SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth <i>in vitro</i> and <i>in vivo</i> and triggers p38 MAP kinase-mediated differentiation. Oncotarget, 2015, 6, 12421-12435.	1.8	21
41	Prostate Cancer and Bone: The Elective Affinities. BioMed Research International, 2014, 2014, 1-14.	1.9	32
42	Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer, 2014, 14, 154.	2.6	92
43	Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis. Experimental Cell Research, 2014, 328, 20-31.	2.6	14
44	Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets. World Journal of Clinical Oncology, 2014, 5, 335.	2.3	17
45	Plasma brainâ€derived neurotrophic factor in earthquake survivors with full and partial postâ€traumatic stress disorder. Psychiatry and Clinical Neurosciences, 2013, 67, 363-364.	1.8	7
46	Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. Journal of Bone and Mineral Research, 2013, 28, 1912-1924.	2.8	21
47	Pyrazolo[3,4- <i>d</i>]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 622-626.	2.8	16
48	Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4- <i>d</i>]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant. Journal of Medicinal Chemistry, 2013, 56, 5382-5394.	6.4	39
49	A Combination Strategy to Inhibit Pimâ€1: Synergism between Noncompetitive and ATP ompetitive Inhibitors. ChemMedChem, 2013, 8, 484-496.	3.2	13
50	Mechanisms Underlying the Anti-Tumoral Effects of Citrus bergamia Juice. PLoS ONE, 2013, 8, e61484.	2.5	60
51	Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs). PLoS ONE, 2013, 8, e79309.	2.5	44
52	Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. Journal of Bone and Mineral Research, 2012, 27, 2387-2398.	2.8	24
53	Molecular Pathology of Cancer Metastasis: Suggestions for Future Therapy. , 2012, , 469-515.		2
54	Roles of Metalloproteases in Metastatic Niche. Current Molecular Medicine, 2011, 11, 609-622.	1.3	67

#	Article	IF	CITATIONS
55	Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancer. Diagnostic Pathology, 2011, 6, 34.	2.0	10
56	Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5928-5933.	2.2	48
57	Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond. Current Medicinal Chemistry, 2011, 18, 2827-2835.	2.4	7
58	EphA2 Induces Metastatic Growth Regulating Amoeboid Motility and Clonogenic Potential in Prostate Carcinoma Cells. Molecular Cancer Research, 2011, 9, 149-160.	3.4	63
59	New pyrazoloâ€[3,4― <i>d</i>]â€pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells. FASEB Journal, 2010, 24, 2881-2892.	0.5	26
60	Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells. BMC Cancer, 2010, 10, 602.	2.6	53
61	Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines. Gynecologic Oncology, 2010, 119, 557-563.	1.4	21
62	Receptor Activator of NF-κB Ligand Enhances Breast Cancer–Induced Osteolytic Lesions through Upregulation of Extracellular Matrix Metalloproteinase Inducer/CD147. Cancer Research, 2010, 70, 6150-6160.	0.9	54
63	Bone-Targeted Doxorubicin-Loaded Nanoparticles as a Tool for the Treatment of Skeletal Metastases. Current Cancer Drug Targets, 2010, 10, 649-659.	1.6	72
64	Targeting ERBB Receptors to Inhibit Metastasis: Old Hopes and New Certainties. Current Cancer Drug Targets, 2009, 9, 1-18.	1.6	6
65	Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1512-1516.	2.2	27
66	Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis. American Journal of Pathology, 2009, 174, 1492-1503.	3.8	96
67	INHIBITION OF 5-ALPHA-REDUCTASE ISOFORMS IN PROSTATE CARCINOMA PRIMARY CULTURES. Journal of Urology, 2009, 181, 397-398.	0.4	11
68	Neuroendocrine transdifferentiation induced by VPA is mediated by PPARÎ ³ activation and confers resistance to antiblastic therapy in prostate carcinoma. Prostate, 2008, 68, 588-598.	2.3	10
69	Effects of Dutasteride on Prostate Carcinoma Primary Cultures: A Comparative Study With Finasteride and MK386. Journal of Urology, 2008, 180, 367-372.	0.4	18
70	Antiproliferative and proapoptotic activities of new pyrazolo[3,4―d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB Journal, 2008, 22, 1560-1571.	0.5	60
71	Arachidonic acid modulates the crosstalk between prostate carcinoma and bone stromal cells. Endocrine-Related Cancer, 2008, 15, 91-100.	3.1	24
72	Targeting Vascular Cell Migration as a Strategy for Blocking Angiogenesis: The Central Role of Focal Adhesion Protein Tyrosine Kinase Family. Current Pharmaceutical Design, 2007, 13, 2129-2145.	1.9	31

5

#	Article	IF	CITATIONS
73	Surgical and Biologic Outcomes After Neoadjuvant Bicalutamide Treatment in Prostate Cancer. Urology, 2007, 70, 728-733.	1.0	35
74	Identification of a Novel Pyrazolo[3,4- <i>d</i>]pyrimidine Able To Inhibit Cell Proliferation of a Human Osteogenic Sarcoma in Vitro and in a Xenograft Model in Mice. Journal of Medicinal Chemistry, 2007, 50, 5579-5588.	6.4	79
75	Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells. European Journal of Cancer, 2006, 42, 2838-2845.	2.8	62
76	Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. International Journal of Oncology, 2006, 28, 909.	3.3	9
77	Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anti-Cancer Drugs, 2006, 17, 1141-1150.	1.4	33
78	Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 161-172.	2.5	126
79	Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer, 2006, 13, 197-210.	3.1	79
80	Osteoblast-conditioned media stimulate membrane vesicle shedding in prostate cancer cells. International Journal of Oncology, 2006, 28, 909-14.	3.3	12
81	Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 243-254.	2.5	8
82	Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. Thrombosis and Haemostasis, 2005, 93, 964-975.	3.4	93
83	Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocrine-Related Cancer, 2005, 12, 983-998.	3.1	49
84	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. International Journal of Oncology, 2005, 26, 1353.	3.3	3
85	Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Therapy, 2005, 12, 702-714.	4.5	67
86	Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. Urology, 2005, 66, 24-28.	1.0	107
87	Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. International Journal of Oncology, 2005, 26, 1353-62.	3.3	2
88	Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. International Journal of Oncology, 2004, 25, 97.	3.3	6
89	Evaluation of metastatic potential in prostate carcinoma: An in vivo model. International Journal of Oncology, 2004, 25, 1713.	3.3	8
90	Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. Journal of Cancer Research and Clinical Oncology, 2004, 130, 217-221.	2.5	24

#	Article	IF	CITATIONS
91	Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate, 2004, 59, 157-166.	2.3	56
92	An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. International Journal of Cancer, 2004, 112, 909-919.	5.1	108
93	Evaluation of metastatic potential in prostate carcinoma: an in vivo model. International Journal of Oncology, 2004, 25, 1713-20.	3.3	12
94	Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. Journal of Cancer Research and Clinical Oncology, 2003, 129, 165-174.	2.5	71
95	Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators. Biological Chemistry, 2002, 383, 229-234.	2.5	33
96	Bombesin-Dependent Pro-MMP-9 Activation in Prostatic Cancer Cells Requires β1 Integrin Engagement. Experimental Cell Research, 2002, 280, 1-11.	2.6	22
97	Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Research, 2002, 22, 2917-22.	1.1	7
98	Osteoblast-derived TGF-Î ² 1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal of Cancer, 2000, 85, 407-415.	5.1	59
99	Osteoblast-derived TCF?-1 modulates matrix degrading protease expression and activity in prostate cancer cells. , 2000, 86, 888-888.		16
100	Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clinical and Experimental Metastasis, 2000, 18, 163-170.	3.3	74
101	Osteoblast conditioned media contain TGF-?1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. , 1999, 81, 395-403.		78
102	Reduction of Glutamate Levels in HIV-Infected Subjects Treated with Acetylcarnitine. Journal of Neuro-AIDS, 1999, 2, 65-73.	0.2	4
103	Osteoblast conditioned media contain TGFâ€Î²1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. International Journal of Cancer, 1999, 81, 395-403.	5.1	1
104	The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death and Differentiation, 1998, 5, 381-389.	11.2	43
105	DIFFERENT APOPTOTIC PATHWAYS ACTIVATED BY DAUNORUBICIN IN HUMAN LYMPHOCYTES AND FIBROBLASTS. Biochemical Society Transactions, 1996, 24, 617S-617S.	3.4	Ο

7